White Paper

Minimizing Luck In Study Feasibility Part 2: Predictive Analytics

By Ashley Schwalje, Senior GTM Manager, Clinical R&D Strategy, Informa Pharma Intelligence and Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence

AI Data iStock-1223789411

Study feasibility is a fundamental contributor to the overall success of a clinical development program. However, selecting the right countries, sites and investigators and starting up as quickly as possible remains a challenge, leading to greatly variable performance and inaccurate predictions for important trial milestones. Current approaches can best be described as a blend of art and science, requiring time-intensive data analysis, deep contextual understanding, and a healthy slice of good fortune to meet enrollment targets. In this article, the second of a two-part series, Informa Pharma Intelligence introduces a first-of-its-kind artificial intelligence (AI) solution for this critical industry problem.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: